Answers are grounded in this paper and cite their sources.
Introduction Lipocalin‐2 is an acute‐phase protein with pleotropic functions that has been implicated in several diseases including Alzheimer's disease (AD). However, it is unknown if circulating lipocalin‐2 levels are altered in the preclinical stage of AD, where AD pathology has accumulated but cognition remains relatively intact. Methods In this cross‐sectional study, we used an immunoassay to measure plasma lipocalin‐2 levels in cognitively normal (Clinical Dementia Rating 0) elderly individuals. 38 of 156 subjects were classified as preclinical AD by cerebrospinal fluid criteria. Results Plasma lipocalin‐2 levels were higher in preclinical AD compared with control subjects and associated with cerebrospinal fluid amyloid‐beta 42 levels but not cerebrospinal fluid tau or phosphorylated‐tau 181 levels. Exploratory analyses revealed that plasma lipocalin‐2 was associated with executive function but not episodic memory. Discussion Collectively, these results raise the possibility that circulating lipocalin‐2 is involved early in AD pathogenesis and may represent an early blood biomarker of amyloid‐beta pathology.
No takes yet. Share an insight, caveat, or question.
Eruysal et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: